Literature DB >> 692579

Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).

J Dean, A N Schechter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 692579     DOI： 10.1056/NEJM197810192991605

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

1.  Alpha thalassemia changes erythrocyte heterogeneity in sickle cell disease.

Authors:  C T Noguchi; G J Dover; G P Rodgers; G R Serjeant; S E Antonarakis; N P Anagnou; D R Higgs; D J Weatherall; A N Schechter
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

2.  Visualization of oriented hemoglobin S in individual erythrocytes by differential extinction of polarized light.

Authors:  W Mickols; M F Maestre; I Tinoco; S H Embury
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

3.  Anaesthesia for renal transplantation in sickle cell disease.

Authors:  H K Gyasi; A W Zarroug; M Matthew; R Joshi; A Daar
Journal:  Can J Anaesth       Date:  1990-10       Impact factor: 5.063

4.  Hydration of sickle cells using the sodium ionophore Monensin. A model for therapy.

Authors:  M R Clark; N Mohandas; S B Shohet
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

5.  Physiological and x-ray studies of potential antisickling agents.

Authors:  D J Abraham; M F Perutz; S E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

6.  Pharmacokinetics and pharmacodynamics of tucaresol, an antisickling agent, in healthy volunteers.

Authors:  P E Rolan; A J Mercer; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

7.  The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects.

Authors:  P E Rolan; J E Parker; S J Gray; B C Weatherley; J Ingram; W Leavens; R Wootton; J Posner
Journal:  Br J Clin Pharmacol       Date:  1993-04       Impact factor: 4.335

8.  Recombinant human sickle hemoglobin expressed in yeast.

Authors:  J J Martin de Llano; O Schneewind; G Stetler; J M Manning
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

9.  Properties of a recombinant human hemoglobin double mutant: sickle hemoglobin with Leu-88(beta) at the primary aggregation site substituted by Ala.

Authors:  J J Martin de Llano; J M Manning
Journal:  Protein Sci       Date:  1994-08       Impact factor: 6.725

10.  Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.

Authors:  T Asakura; S T Ohnishi; K Adachi; M Ozguc; K Hashimoto; M Singer; M O Russell; E Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.